Maxim Group restated their buy rating on shares of Viveve Medical Inc (NASDAQ:VIVMF) in a research report sent to investors on Thursday. They currently have a $11.00 price objective on the stock.

COPYRIGHT VIOLATION WARNING: This report was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at

Viveve Medical Company Profile

Viveve Medical, Inc, formerly PLC Systems, Inc, designs, develops, manufactures and markets medical devices for the non-invasive treatment of vaginal introital laxity. The Company’s Viveve Treatment is a non-invasive solution for vaginal laxity that is performed in around 30 minutes in a physician’s office.

Receive News & Stock Ratings for Viveve Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc and related stocks with our FREE daily email newsletter.